

| |
|--------------------------------------|
| PATENT ASSIGNMENT COVER SHEET |
|--------------------------------------|

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6722017

| | |
|---|--|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| JAMES PHILIP O'CONNELL | 07/01/2020 |
| ALASTAIR LAWSON | 07/01/2020 |
| JOHN ROBERT PORTER | 07/01/2020 |
| DANIEL JOHN LIGHTWOOD | 07/01/2020 |
| REBECCA JAYNE MUNRO | 07/01/2020 |
| RECEIVING PARTY DATA | |
| Name: | UCB BIOPHARMA SRL |
| Street Address: | ALLÉE DE LA RECHERCHE 60 |
| City: | BRUSSELS |
| State/Country: | BELGIUM |
| Postal Code: | 1070 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 17325036 |
| CORRESPONDENCE DATA | |
| Fax Number: | (703)712-8525 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | (703) 712-8531 |
| Email: | admin@medlerferro.com, docketing@medlerferro.com |
| Correspondent Name: | MEDLER FERRO WOODHOUSE & MILLS PLLC |
| Address Line 1: | 8201 GREENSBORO DRIVE |
| Address Line 2: | SUITE 1060 |
| Address Line 4: | MCLEAN, VIRGINIA 22102 |
| ATTORNEY DOCKET NUMBER: | 1089-0006US2 |
| NAME OF SUBMITTER: | CYNTHIA M. BOUCHEZ |
| SIGNATURE: | /Cynthia M. Bouchez/ |
| DATE SIGNED: | 05/21/2021 |
| Total Attachments: 15 | |

source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page1.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page2.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page3.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page4.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page5.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page6.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page7.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page8.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page9.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page10.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page11.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page12.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page13.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page14.tif
source=1089-0006US2 - Assignment - Inventors to UCB Biopharma SRL#page15.tif

THIS DEED is made the 1 day of July 2020

BETWEEN:

(1) JAMES PHILIP O'CONNELL, a British citizen; ALASTAIR LAWSON, a British citizen; JOHN ROBERT PORTER, a British citizen; DANIEL JOHN LIGHTWOOD, a British citizen; REBECCA JAYNE WOOTTON, a British citizen, all c/o IPD, UCB Celltech, 208 Bath Road, Slough, Berkshire, SL1 3WE, United Kingdom (hereinafter referred to as "the Celltech R&D Inventors"); and TRACY LYNN ARAKAKI, a US citizen, c/o Beryllium, 7869 N.E. Day Road West, Bainbridge Island, WA 98110, United States of America (hereinafter referred to as "a Beryllium Inventor") (the Celltech R&D Inventor and the Beryllium Inventors hereinafter collectively referred to as "the Inventors" which expression where the context so allows shall include their personal representatives and assigns);

(2) CELLTECH R&D LIMITED, a company incorporated under the laws of England and Wales and having its registered office at 208 Bath Road, Slough, Berkshire, SL1 3WE, United Kingdom (hereinafter called "Celltech R&D" which expression where the context so allows shall include its successors and assigns);

(3) UCB BIOSCIENCES, INC., a US corporation organized and existing under the laws of Delaware having its principal place of business at 8010 Arco Corporate Drive, Raleigh, NC 27617, USA and successor by merger to BERYLLIUM DISCOVERY CORPORATION (formerly known as deCODE biostructures, Inc. and Emerald Biostructures, Inc.), a US corporation organised under the laws of the State of Washington and having its principal office at 7869 NE Day Road West, Bainbridge Island, WA 98110, United States of America (hereinafter called "Beryllium" which

expression where the context so allows shall include its successors and assigns); and

(4) UCB BIOPHARMA SRL, a Belgian body corporate (formerly known as UCB Biopharma SPRL), having its registered office at Allée de la Recherche 60, B-1070 Brussels, Belgium (hereinafter called "UCB Biopharma" which expression where the context so allows shall include its successors and assigns).

WHEREAS:

(A) On April 1, 2019, BERYLLIUM DISCOVERY CORPORATION merged with and into UCB Biosciences, Inc., a US corporation organized and existing under the laws of Delaware having its principal place of business at 8010 Arco Corporate Drive, Raleigh, NC 27617, USA and UCB Biosciences, Inc. succeeded to all of the assets, rights, powers and property of Beryllium in accordance with Section 259 of the General Corporate Law of the State of Delaware.

(B) On 2 December 2019 the new Belgian Code of Companies and Associations became effective and imposed a mandatory change of the name of the legal form of the entities from "*société privée à responsabilité limitée*", abbreviated "*SPRL*" to *société à responsabilité limitée*", abbreviated "*SRL*". This mandatory change has no other legal consequences. As a result of such change, the legal form UCB Biopharma SPRL is now referred to as UCB Biopharma SRL.

(C) The Inventors claim to be joint inventors of an invention entitled "ANTIBODY EPITOPE" ("the Invention") full particulars of which have been communicated by them to Celltech R&D or Beryllium respectively and which they are informed is or is intended to be the subject of one or more applications for patent protection filed in the name of UCB Biopharma as identified in the Schedule hereto and in respect of which they have (as they hereby acknowledge) approved a specification as submitted to them by UCB Biopharma's Patent Attorneys, J A Kemp.

(D) The Celltech R&D Inventors made their contribution to the Invention while in the employment of Celltech R&D either in the course of their normal duties or in the course of duties

falling outside their normal duties but specifically assigned to them and the circumstances in either case were such that an invention might reasonably be expected to result from the carrying out of their duties or in the course of their duties and because of the nature of their duties and the particular responsibilities arising from the nature of their duties they had a special obligation to further the interests of Celltech R&D's undertaking and accordingly all their right title share and interest in and to the Invention is to be taken (as between each of the Celltech R&D Inventors and Celltech R&D) to belong to Celltech R&D for the purposes of the Patents Act 1977 and for all other purposes of whatsoever nature.

(E) By reason of an Employee and IP Services Agreement dated 27 May 2005 between Celltech R&D and UCB S.A.; a Contribution of Assets made by UCB S.A. to UCB Pharma S.A. through a Notarial Deed dated 20 December 2006 and a Deed of Novation dated 20 December 2006 between Celltech R&D, UCB S.A. and UCB Pharma S.A.; and a Contribution of Assets made by UCB Pharma S.A. to UCB Biopharma through a Notarial Deed and its annexes dated 30 April 2014, it is agreed that all Celltech R&D's right title share and interest in and to the Invention including the full right to apply for and obtain a patent or patents or other similar forms of protection in respect of the Invention both in the United Kingdom and in all other countries of the world belongs to UCB Biopharma.

(F) Tracy Lynn Arakaki made her contribution to the Invention while in the employment of Emerald BioStructures, Inc., formerly deCODE biostructures, Inc. Their rights belong, by virtue of employment, to Emerald BioStructures, Inc. Pursuant to research agreements between deCODE chemistry Inc., deCODE biostructures, Inc., Emerald Biostructures, Inc. and UCB Pharma S.A., Emerald Biostructures, Inc.'s rights belong to UCB Pharma S.A [7th January 2009].

(G) Pursuant to consecutive research agreements between Beryllium of the one part and UCB Pharma S.A. of the other part it is agreed that all Beryllium's right title share and interest in and to the Invention including the right to apply for and obtain a patent or patents or other similar forms of protection in respect of the Invention both in the United Kingdom and in all other countries of

the world belongs to UCB Pharma S.A. Furthermore, pursuant to a Contribution of Assets made by UCB Pharma S.A. to UCB Biopharma through a Notarial Deed and its annexes dated 30 April 2014, it is agreed that all UCB Pharma S.A.'s right title share and interest in and to the Invention including the full right to apply for and obtain a patent or patents or other similar forms of protection in respect of the Invention both in the United Kingdom and in all other countries of the world belongs to UCB Biopharma.

(H) The Celltech R&D Inventors have agreed at the request of Celltech R&D; the Beryllium Inventor has agreed at the request of Beryllium, and Celltech R&D and Beryllium have agreed at the request of UCB Biopharma to execute this Deed on the terms herein contained.

NOW THIS DEED WITNESSES as follows:

1. In pursuance of the said agreement and in consideration of the premises the Inventors, Celltech R&D and Beryllium HEREBY JOINTLY AND SEVERALLY and to the extent of their respective shares and interests therein ASSIGN and CONFIRM unto UCB Biopharma ALL THOSE their respective right title share and interest in and to the Invention and the patent applications identified in the Schedule hereto and all patents granted thereon AND in any and all applications that claim the benefit of the patent applications identified in the Schedule, including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed in the Schedule, to the full extent of the term or terms for which Letters Patents issue, AND the full and exclusive benefit thereof TOGETHER WITH all rights of action and powers accruing or belonging to the Inventors, Celltech R&D or Beryllium AND the full right to apply for and obtain a patent or patents or other similar forms of protection in respect of the Invention both in the United Kingdom and in all other countries of the world including the benefit of any priority date and the right to make applications whether under any

national law or under the International Convention for the Protection of Industrial Property or under any other applicable convention or treaty TO HOLD the same unto UCB Biopharma absolutely.

2. The Inventors, Celltech R&D and Beryllium HEREBY JOINTLY and SEVERALLY COVENANT and AGREE with UCB Biopharma as follows: -

(a) that they will at any time hereafter (whether or not the Inventors remain in the employ of Celltech R&D or Beryllium as the case may be) and from time to time at the request of UCB Biopharma promptly execute and sign all such instruments applications and documents and do all such acts and things as may be required by UCB Biopharma to enable UCB Biopharma to enjoy the full benefit of the rights hereby confirmed and assigned including applying for and obtaining a patent or patents or other similar forms of protection in respect of the Invention both in the United Kingdom and in all other countries of the world and vesting the same in UCB Biopharma or its nominees when obtained;

(b) that they have not assigned or agreed to assign to any person firm or company other than UCB Biopharma or otherwise encumbered and will not hereafter assign or agree to assign to any person firm or company or otherwise encumber the Invention or the said patent applications or the right to apply for or obtain a patent or patents or other similar forms of protection in respect thereof in the United Kingdom or elsewhere throughout the world;

(c) that they will give to UCB Biopharma all such information in their possession or in their power relating to the Invention and the method of using or employing the same as UCB Biopharma shall require; and

(d) that they have not disclosed and will not hereafter disclose the Invention or any

information whatsoever concerning the same to any person firm or company other than Celltech R&D, Beryllium, UCB Biopharma or UCB Biopharma's Patent Attorneys, J A Kemp.

3. This document shall be governed by and construed in accordance with English Law.

IN WITNESS whereof this Instrument has been executed by the parties as a Deed in the presence of the persons mentioned below the day and year first before written.

SCHEDULE

| <u>Patent Application</u> | <u>Application Number</u> | <u>Application Date</u> | <u>grant date or number</u> |
|-------------------------------|-------------------------------|-----------------------------|---------------------------------|
| United Kingdom | 1510758.4 | 18 June 2015 | |
| International | PCT/EP2015/074532 | 22 October 2015 | |
| United States | 15/736,558 | 22 October 2015 | |

SIGNED and DELIVERED as his Deed)
by the said PHILIP JAMES O'CONNELL)
in the presence of: -)

Witness Signature.....

Witness' Name.....

Address.....

.....

.....

Occupation.....

Philip James O'Connell

Stephen Rapecki

W.D.

STEPHEN RAPECKI


2C KIMBERS DRIVE

BURNHAM, BUCKINGHAMSHIRE

SL1 8JE

SCIENTIST

SIGNED and DELIVERED as his Deed)
by the said ALASTAIR LAWSON)
in the presence of: -)



Witness Signature: Rebecca Corbett

Witness' Name: REBECCA CORBETT

Address: HOLDSWORTH FARM

CHERRITON


NE. AYLESFORD

Occupation: FARMER

SIGNED and DELIVERED as his Deed)
by the said JOHN ROBERT PORTER)
in the presence of: -)



Witness Signature



Witness' Name

J. NEWMAN

Address

S. FARM PLACE


HENTON

CHINNOR OX39 4AD

Occupation


NHS MANAGER

SIGNED and DELIVERED as his Deed by)
the said DANIEL JOHN LIGHTWOOD)
in the presence of: -)


.....

Witness Signature J. Murray.....
Witness' Name JANINE MURRAY.....
Address 216 BATH ROAD.....
..SLOUGH, SLI. 3WE.....
.....
Occupation RESEARCH SCIENTIST...

SIGNED and DELIVERED as her Deed by)
the said REBECCA JAYNE WOOTTON)
in the presence of: -)


.....

MARRIAD NAME: REBECCA JAYNE MUNRO

Witness Signature S. Tickle
Witness' Name Simon Tickle
Address 8 Mill Reef Close
Thetford
Berkshire
Occupation Scientist

SIGNED and DELIVERED as her Deed)
by the said TRACY LYNN ARAKAKI)
in the presence of: -)

.....

Witness Signature.....
Witness' Name.....
Address
.....
.....
Occupation.....

SIGNED and DELIVERED as a Deed by
CELLTECH R&D LIMITED acting by
a Director in the presence of: -

)
) 
)

Yogesh Khatri
Director

Witness Signature 

Witness' name VIRAL SHAH


Address 208 BATA ROAD

SLAVEN

SLI ZWE



Occupation CHARTERED ACCOUNTANT / CHARTERED TAX ADVISER

SIGNED and DELIVERED as a Deed by)
UCB BIOSCIENCES, INC., successor by merger)
to BERYLLIUM DISCOVERY CORPORATION)
by a person acting under the authority of such)
company in accordance with the laws of the state)
in which it is incorporated)




...Jennifer L. Trevett.....

Title: Head of Legal US & Global Immunology

Witness Signature.....
Witness' Name..... Thomas Trevett
Address..... 4821 CLUB VALLEY DR
..... ATLANTA, GA
..... 30319
Occupation..... 

SIGNED and DELIVERED as a Déed by)
UCB BIOPHARMA SRL by a person)
acting under the authority of such company)
in accordance with the laws of the territory)
in which it is incorporated)



Stéphane DROUIN

Title: Proxy and Legal Representative

Witness Signature.....


Witness' Name.....*Stéphane Drouin*

Address.....*UCB Biopharma SRL*
Allée de la Recherche, 60
B-1070 Brussels - Belgium

Occupation.....*Stéphane Drouin* *PROXY AND LEGAL REPRESENTATIVE*